Table 4.

Comparison of median PFS and OS reported in the current study with that reported in literature.

Author	n	Region	Arms	PFS in months	OS in months	Second line received*
Rosell et al3	173	Europe	Erlotinib	9.7	19.3	NR
			Docetaxel or gemcitabine with either cisplatin or carboplatin	5.2	19.5	76%
Zhou et al4	165	China	Erlotinib	13.1	22.8	NR
			Gemcitabine with carboplatin	4.6	27.2	NR
Maemondo et al5	230	Japan	Gefitinib	10.8	30.5	67.5%
			Paclitaxel/carboplatin	5.4	23.6	94.6%
Mitsudomi et al6	177	Japan	Gefitinib	9.2	30.9	NR
			Docetaxel/cisplatin	6.3	NR	NR
Sequist et al7	345	East Asia, Europe, Australia	Afatinib	11.1	NR	NR
			Pemetrexed/cisplatin	6.9	NR	NR
Current study	290	India	Gefitinib	8.4	18	63.8%
			Pemetrexed carboplatin followed by pemetrexed maintenance	5.6	22.6	93.6%

*The percentage of patients who received second line among patients who were eligible for same.

NR, not reported; OS, overall survival; PFS, progression-free survival.